Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas: Aspects of carcinogenesis and prognostic significance

Cancer

Volumn 77, Issue 2, 1996, Pages 255-264

  Baretton, Gustavo Bruno ^a   Diebold, Joachim ^a   Christoforis, Gregor ^a   Vogt, Michael ^a   Müller, Christian ^b   Dopfer, Karin ^a   Schneiderbanger, Karin ^a   Schmidt, Michael ^c   Löhrs, Udo ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

adenoma; apoptosis; bcl 2; carcinoma; colon; immunohistochemistry; Ki 67; p53; prognosis; proliferation; protooncogene; rectum

Indexed keywords

PROTEIN BCL 2;

APOPTOSIS; ARTICLE; COLON ADENOMA; COLON CARCINOGENESIS; COLORECTAL CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RECTUM ADENOMA;

ADENOMA; AGED; APOPTOSIS; CARCINOMA; COLORECTAL NEOPLASMS; FEMALE; HUMANS; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PARAFFIN; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030024253     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960115)77:2<255::AID-CNCR6>3.0.CO;2-L     Document Type: Article

References (50)

1. Kerr JFR, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy. Cancer 1994;73:2013-36.
2. Reed JC. Bcl-2 and the regulation of programmed cell death. J Cell Biol 1994;124:1-6.
3. Kerr JF, Wyllie AH. Currie AR. Apoptosis: A basic biological phenomen with wide-ranging implications in tissue kinetics. Br J Cancer 1972;26:239-57.
4. Stewart BW. Mechanisms of apoptosis: Integration of genetic, biochemical, and cellular indicators. J Natl Cancer Inst 1994;86:1286-96.
5. Chandler D, el Naggai AK, Brisbay S, Redline RW, McDonnell TJ. Apoptosis and expression of the bcl-2 proto-onco-gene in the fetal and adult human kidney: Evidence for the contribution of bcl-2 expression to renal carcinogenesis. Hum Pathol 1994;25:789-96.
6. Korsmeyer SJ. Bcl-2 initiates a new category of oncogenes: Regulators of cell death. Blood 1992;80:879-86.
7. Oren M. The involvement of oncogenes and tumor suppressor genes in the control of apoptosis. Cancer Metastasis Rev 1992;11:141-8.
8. Tsujimoto Y, Croce CM. Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA 1986;83:5214-8.
9. Tsujimoto Y, Ikegaki N, Grace CM. Characterization of the protein product of bcl-2, the gene involved in human follicular lymphoma. Oncogene 1987;2:3-7.
10. McDonnell TJ, Nunez G, Platt FM, Hockenbery DM, London L, McKearn JP, et al. Deregulated bcl-2-immunoglobulin transgene expands a resting but responsive immunoglobulin M and D expression B-cell population. Mol Cell Biol 1990;10:1901-7.
11. Pezzella F, Turley H, Kuzu I, Tungekar MF, Dunnhill MS, Pierce CB, et al. bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med 1993;329:690-4.
12. Ben Ezra JM, Kornstein MJ, Grimes MM, Krystal G. Small cell carcinomas of the lung express the bcl-2 protein. Am J Pathol 1994;145:1036-40.
13. Pilotti S, Collini P, Del Bo R, Cattoretti G, Pierotti MA, Rilke F. A novel panel of antibodies that segregates immunocytochemically poorly differentiated carcinoma from undifferentiated carcinoma of the thyroid gland. Am J Surg Pathol 1994;18:1054-64.
14. Doglioni C, Deitos AP, Laurino L, Chiarelli C, Barbareschi M, Viale G. The prevalence of bcl-2-immunoreactivity in breast carcinomas and its clinicopathological correlates, with particular reference to oestrogen receptor status. Virchows Arch 1994;424:45-51.
15. Lauwers GY, Scott GV, Karpeh MS. Immunohistochemical evaluation of bcl-2 protein expression in gastric adenocarcinomas. Cancer 1995;75:2209-13.
16. Kuwashima Y, Uehara T, Kishi K, Shiromizu K, Matsuzawa M, Takayama S. Immunohistochemical characterization of undifferentiated carcinomas of the ovary. J Cancer Res Clin Oncol 1994;120:672-7.
17. Thomas RM, Sobin LH. Gastrointestinal cancer. Cancer 1995;75(Suppl.):154-70.
18. Statistisches Bundesamt: Statistisches Jahrbuch 1993 für die Bundesrepublik Deutschland (German Federal Office for Statistics. Statistical Yearbook 1993 for the Federal Republic of Germany). Wiesbaden: Statistisches Bundesamt, 1993.
19. Fenoglio CM, Lane N. The anatomical precursor of colorectal carcinoma. Cancer 1974;34:819-23.
20. Muto T, Bussey HJR, Morson BC. The evolution of cancer of the colon and rectum. Cancer 1975;36:2251-70
21. Hermanek P, Frühmorgen P, Guggenmoos-Holzmann I. The malignant potential of colorectal polyps-a new statistical approach. Endoscopy 1983;15:16-20.
22. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectaltumor development. N Engl J Med 1988;319:525-32.
23. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61.759-67.
24. Eastwood GL. Gastrointestinal epithelial renewal. Gastroenterology 1977;72:962-75.
25. Eastwood GL. Epithelial renewal in premalignant conditions of the gastrointestinal tract: A review. J Clin Gastroenterol 1992; 14(Suppl. i):S29-33.
26. Diebold J, Lai MD, Löhrs U. Analysis of proliferative activity in colorectal mucosa by Immunohistochemical detection of proliferating cell nuclear antigen (PCNA). Virchows Arch [B] 1992;62:283-9.
27. Diebold J, Dopfer K, Lai MD, Löhrs U. Comparison of different monoclonal antibodies for the immunohistochemical assessment of cell proliferation in routine colorectal biopsy specimens. Scand J Gastroenterol 1994;29:47-53.
28. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identificacion of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992; 119;493-501.
29. Lane DP. p53, guardian of the genome. Nature 1992;358:15-6.
30. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell 1992;70:523-6.
31. Baretton G, Vogt M, Diebold J, Müller C, Schmidt M, Löhrs U. Prognostic significance of DNA ploidy, numerical chromosome 17 aberrations and p53 expression in colorectal carcinomas. Pathol Res Pract 1994;190:265 (152).
32. Sinicrope FA, Ruan SB, Cleary KR, Stephens LC, Lee JJ, Levin B. bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res 1995;55:237-41.
33. UICC, International Union Against Cancer. TNM-atlas: illustrated guide to the TNM/pTNM-classification of malignant tumors. New York: Springer, 1993.
34. Jass JR, Sobin LH. Histological typing of intestinal tumours. World Health Organization. International Classification of Tumours. New York: Springer, 1989.
35. Ansari B, Coates PJ, Greenstein BD, Hall PA. In situ end-labeling detects DNA strand breaks in apoptosis and other physiological and pathological states. J Pathol 1993;170:1-8.
36. Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983;31:13-20.
37. Gerdes J, Lemke H, Baisch H, Wacker H-H, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984;133;1710-5.
38. Cordell JL, Falini B, Erber WN, Ghosh AK, Abdulaziz Z, McDonald S, et al. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 1984;32:219-29.
39. Pezzella F, Tse AGD, Cordell JL, Pulford KAF, Gatter KC, Mason DY. Expression of the bcl-2 oncogene is not specific for the 14:18 chromosomal translocation. Am J Pathol 1990;137:225-32.
40. Yin XM, Oltval ZN, Korsmeyer SJ. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature 1994;369:321-3.
41. Chleq Deschamps CM, LeBrun DP, Huie P, Besnier DP, Warnke RA, Sibley RK, et al. Topographical dissociation of BCL-2 messenger RNA and protein expression in human lymphoid tissues. Blood 1993;81:293-8.
42. Hockenbery DM, Zutter M, Hickey W, Nahm M, Korsmeyer SJ. bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 1991;88:6961-5.
43. LeBrun DP, Warnke RA, Cleary ML. Expression of bcl-2 in fetal tissues suggests a role in morphogenesis. Am J Pathol 1993;142:743-53.
44. Benedetti A, Mancini R, Marucci L, Paolucci F, Jezequel AM, Orlandi F. Alimentary tract and pancreas: Quantitative study of apoptosis in normal rat gastroduodenal mucosa. J Gastroenterol Hepatol 1990;5:369-74.
45. Lauwers GY, Scott GV, Hendricks J. Immunohistochemical evidence of aberrant bcl-2 protein expression in gastric epithelial dysplasia. Cancer 1994;73:2900-4.
46. Bosari S, Moneghini L, Graziani D, Lee AKC, Murray JJ, Coggi G, et al. bcl-2 oncoprotein in colorectal hyperplastic polyps, adenomas, and adenocarcinomas. Hum Pathol 1995; 26:534-40.
47. Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, et al. Induction of apoptosis in fibroblasts by cmyc protein. Cell 1992;69:119-28.
48. cdc2 activation required for apoptosis. Science 1994;1143-5.
49. Sander CA, Yano T, Clark HM, Harris C, Longo DL, Jaffe ES, et al. p53 mutation is associated with progression in follicular lymphomas. Blood 1993;82:1994-2004.
50. Diebold J, Baretton G, Felchner M, Meier W, Dopfer K, Schmidt M, et al. Bcl-2 Expression und Apoptose in Ovarialtumoren (Bcl-2 expression and apoptosis in ovarian tumors). Verh Dtsch Ges Pathol 1994;78:641.